Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1644 (eOD-GT8 60mer) in HIV-uninfected adults
NCT05414786Phase 1Unknown
- Sponsor
- International AIDS Vaccine Initiative
- Start
- May 2022
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of eOD-GT8 60mer mRNA vaccine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by International AIDS Vaccine Initiative. Primary endpoints: Safety and tolerability of eOD-GT8 60mer mRNA Vaccine at 16 months and VRC01-class IgG B-cells at 16 months. Status: unknown.
02
Drugs
eOD-GT8 60mer mRNA vaccine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05414786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05414786.